Trial Profile
A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 26 Mar 2018 The protocol was amended to enroll an additional 20 patients in a high-dose temozolomide cohort (200 mg/m2/d orally on days 1-5 of each 28-day cycle), according to result published in the Cancer.
- 26 Mar 2018 Primary endpoint (Disease control rate) has been met, according to results published in the Cancer.
- 26 Mar 2018 Results (n=75) assessing the efficacy and tolerability of temozolomide [Temodar] + veliparib [ABT-888; Abbott Laboratories] in patients heavily pretreated, metastatic with colorectal cancer, were published in the Cancer.